Resultado da Busca
25 de out. de 2022 · Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.
Há 5 dias · e15544 Background: Immune checkpoint inhibitors (ICIs) are the gold standard therapy in metastatic colorectal cancer (mCRC) patients (pts) with microsatellite instability (MSI). The Colon-MSI study aimed to describe a cohort of MSI mCRC pts treated with ICIs before Italian pembrolizumab approval and to evaluate the efficacy, safety, and possible predictive factors of response in a real-world ...
Depiction of the three immune archetypes of colorectal cancer (CRC) metastasis: immune-inflamed, immune-excluded and immune-desert130. Associated cell types and mechanisms are indicated. The ...
17 de out. de 2022 · PDF. Abstract. Purpose. To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). Methods. ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. Results.
Há 6 dias · Despite extensive research and improvements in understanding colorectal cancer (CRC), its metastatic form continues to pose a substantial challenge, primarily owing to limited therapeutic options ...
25 de out. de 2022 · Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up5 A. Cervantes1,2, R. Adam3, S. Roselló1,2, D. Arnold4, N. Normanno5, J. Taïeb6,7, J. Seligmann8, T. De Baere9,10,11, P. Osterlund12,13, T. Yoshino14 & E. Martinelli15, on behalf of the ESMO Guidelines Committee*
Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular ...
